We advertise for applications for grants-in-aid at the start of each year (for funding to start in January the following year).

Grants-in-aid support research for 1 to 3 years. They're awarded based on each project's:

  • relevance to cancer,
  • excellence,
  • the value of the research, and
  • the researcher's capacity to successfully complete the research described in the application.

All applications go through a rigorous peer-review process. The state Cancer Councils work in partnership with the National Health and Medical Research Council, which provides us with assessments and rankings.

In 2016 Cancer Council Victoria spent $3.2 million on grants-in-aid. Current recipients are listed below.

Dr Yuan Cao
The University of Melbourne (Peter MacCallum Cancer Centre)
Contribution of platelet factor 4 to inhibition of metastasis driven by bone morphogenetic protein 4 (2016-17) 

Dr Colin Clyne, Dr Ashwini Chand, Prof Evan Simpson
Hudson Institute of Medical Research
LRH-1: a novel driver of breast cancer proliferation (2015-17)

A/Prof Phillip Darcy, A/Prof Michael Kershaw
Peter MacCallum Cancer Centre
Enhancing activation and trafficking of T cells for cancer therapy (2015-17)

Dr Urmi Dhagat, Dr Sophie Broughton, Prof Michael Parker, A/Prof Louise Purton
St Vincent's Institute of Medical Research
Structural linkage between ligand discrimination and receptor activation by interleukin-3 (2017-19) 

Prof Peter Fuller, Dr Ann Drummond, Dr Morag Young, Prof Christine Clarke
Hudson Institute of Medical Research
Non-classical mineralocorticoid receptor signalling in reproductive tissues (2015-17)

A/Prof Hui Gan, Prof Andrew Scott, Prof John Mariadason, A/Prof Elgene Lim, Prof Niall Tebbutt
La Trobe University
Anti-EGFR drug conjugates for the treatment of colorectal and breast cancer  (2017-19) 

Prof Suzanne Garland, Prof Sepehr Tabrizi, A/Prof Richard Hillman, Dr Alyssa Cornall, Dr Fengyi Jin, Dr Jennifer Roberts, Dr Isobel Poynten, Dr Monica Molano, Dr Dorothy Machalek
The University of Melbourne
Evaluating molecular biomarkers of anal cancer risk (2017-19) 

A/Prof Simon Harrison, Prof Ross Hannan, A/Prof Andrew Wei
Peter MacCallum Cancer Centre
Novel approaches to treat refractory haematological malignancies (2015-17)

A/Prof Kieran Harvey, Dr Nicola Waddell, A/Prof Kaylene Simpson
Peter MacCallum Cancer Centre
Deciphering the role of the Hippo pathway in mesothelioma
Lyall Watts Mesothelioma Research Grant (Sept 2016 - Aug 2019)

Prof Ygal Haupt, Dr Shahneen Sandhu
The University of Melbourne
Restoration of tumour suppression in prostate cancer by targeting the ubiquitin proteasome system (2015-17)

Dr Nicole Haynes, Prof Ricky Johnstone, A/Prof Sherene Loi
The University of Melbourne (Peter MacCallum Cancer Centre)
Harnessing the immune system with epigenetic therapies to treat HER2+ breast cancer (2016-18)

Prof John Hopper, Dr Daniel Schmidt, Dr Enes Makalic, Dr Carmel Apicella, Dr Louise Keogh, Dr Helen Frazer, Dr Pierre-Antoine Dugue, Dr Ralph Highnam, Mr Kevin Nguyen, Dr Jill Evans
The University of Melbourne
Development of automated measures from mammograms that predict masking and risk and pilot implementation into a BreastScreen service  (2017-19)

Dr Peter Janes, Prof Dimitar Nikolov, Dr Elgene Lim
Monash University
Novel therapeutic antibodies to fight drug resistant breast cancers  (2016-18)

Dr Peter Janes, Prof Andrew Scott, A/Prof Thomas John
Monash University
Targeted antibody therapy for malignant mesothelioma 
Lyall Watts Mesothelioma Research Grant (2017-2019)

Dr Gemma Kelly
The Walter and Eliza Hall Institute of Medical Research
Investigating the function of the EBV-encoded BCL-2 homologue, BHRF1 (2015-17)

Dr Ian Majewski, Prof David Huang, Prof Andrew Roberts
The Walter and Eliza Hall Institute of Medical Research
Identifying and overcoming resistance to BCL2 inhibitors (2017-19) 

Dr James Murphy, Dr Silvia Alvarez-Dias, A/Prof Matthias Ernst
The Walter and Eliza Hall Institute of Medical Research
The role of the essential necroptosis effector, MLKL, in gastrointestinal tumorigenesis (2015-17)

Dr Kate Murphy, Prof John Silke, Prof Gordon Lynch, Prof Leanne Delbridge
The University of Melbourne
Using novel Fn14 inhibitory antibodies to treat cardiac cachexia in cancer (2017-19)

Prof Stephen Nutt, A/Prof Lynn Corcoran
The Walter and Eliza Hall Institute of Medical Research
Identification of new therapeutic targets in plasma cells and multiple myeloma  (2016-18)

Dr Lan Nguyen
Monash University
Friend or foe? Deciphering the conflicting functions of YAP in breast cancer (2017-19) 

Dr Belinda Parker, A/Prof Phil Darcy
La Trobe University
Type 1 interferon regulators as prognostic markers and predictors of therapeutic response in triple negative breast cancer (2017-19) 

Dr Gretchen Poortinga, Prof Grant McArthur, Prof Ross Hannan
Peter MacCallum Cancer Centre
Elucidating mechanisms of resistance to therapeutic inhibition of RNA polymerase 1 transcription (2016-18) 

A/Prof Louise Purton, Dr Meaghan Wall, Dr Carl Walkley
St Vincent's Institute of Medical Research
Impact of deregulated HOXA1 splicing in myelodysplastic syndromes (2016-18)

A/Prof Helena Richardson, A/Prof Patrick Humbert, Prof Josef Penninger
La Trobe University
Regulation of cell polarity and tumourigenesis by Tetraspanin 6  (2017-19)

Prof Jamie Rossjohn, Prof Andrew Brooks
Monash University
Exploring the role of human Natural Killer cells in tumour immunity (2016-18)

Dr Mark Shackleton, A/Prof Kieran Harvey
Peter MacCallum Cancer Centre
Melanoma and the Hippo pathway (2015-17)

Dr Karen Sheppard, Prof Grant McArthur
Peter MacCallum Cancer Centre
Acquired resistance to CDK4 inhibition in melanoma  (2016-18)

Dr Jake Shortt, Prof Ricky Johnstone
Peter MacCallum Cancer Centre
Overcoming resistance to bromodomain inhibition in MYC driven lymphoma (2015-17)

Prof Andreas Strasser, Dr Daniel Gray
The Walter and Eliza Hall Institute of Medical Research
The mechanisms of cell competition that suppress cancer development (2016-18)

Dr Adam Uldrich, Dr Daniel Pellicci, Dr Ilia Voskoboinik
The University of Melbourne
The functional characterisation and anti-cancer potential of a novel subset of human gamma delta T cells (2017-19) 

Prof Jose Villadangos, Prof William Heath
The University of Melbourne
Characterisation and prevention of "Stunning", a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer (2016-18)

Dr Michaela Waibel, Prof Ricky Johnstone, Prof John Seymour
Peter MacCallum Cancer Centre
Rational combination therapies for JAK-driven haematological malignancies (2015-17)

A/Prof Carl Walkley, A/Prof Wallace Langdon, Dr Meaghan Wall, Dr Alistair Chalk
St Vincent's Institute of Medical Research
Understanding how changes in RNA splicing contribute to myelodysplastic syndrome and chronic myelomonocytic leukaemia (2017-19) 

Dr Florian Wiede
Monash University
PTPN2 and adoptive T cell immunotherapy (2016-18)